Cargando…

Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial

AIMS: Worsening renal function may impact long‐term outcomes in heart failure (HF). However, little is known about the longitudinal trajectories in renal function in relation to HF hospitalization or how this high‐risk clinical event impacts renal outcomes. METHODS AND RESULTS: In PARAGON‐HF, we eva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatur, Safia, Vaduganathan, Muthiah, Peikert, Alexander, Claggett, Brian L., McCausland, Finnian R., Skali, Hicham, Pfeffer, Marc A., Beldhuis, Iris E., Kober, Lars, Seferovic, Petar, Lefkowitz, Martin, McMurray, John J.V., Solomon, Scott D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2022
Materias:	Focused Issue on Clinical Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086974/ https://www.ncbi.nlm.nih.gov/pubmed/35895867 http://dx.doi.org/10.1002/ejhf.2638

Ejemplares similares

Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
por: Peikert, Alexander, et al.
Publicado: (2022)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
por: Wijkman, Magnus O., et al.
Publicado: (2022)

Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF
por: Mooney, Leanne, et al.
Publicado: (2021)

Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
por: Vaduganathan, Muthiah, et al.
Publicado: (2023)

Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER
por: Desai, Akshay S., et al.
Publicado: (2022)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
por: Lund, Lars H., et al.
Publicado: (2021)

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2016)

Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
por: Mogensen, Ulrik M., et al.
Publicado: (2018)

Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial
por: Chatur, Safia, et al.
Publicado: (2023)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction
por: Cannon, Jane A., et al.
Publicado: (2016)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER
por: Butt, Jawad H, et al.
Publicado: (2023)

Geographic variations in the PARADIGM-HF heart failure trial
por: Kristensen, Søren Lund, et al.
Publicado: (2016)

Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM‐HF
por: Yeoh, Su E., et al.
Publicado: (2020)

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Chatur, Safia, et al.
Publicado: (2023)

Interpreting Nonrandomized Evidence for Clinical Decision Making in Cardio-Oncology
por: Chatur, Safia, et al.
Publicado: (2023)

A rationale for dedicated trials of combination therapy in heart failure
por: Blumer, Vanessa, et al.
Publicado: (2022)

Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
por: Jhund, Pardeep S., et al.
Publicado: (2022)

Impact of COVID-19 on Heart Failure Clinical Trials: Insights From the Heart Failure Collaboratory
por: Bhatt, Ankeet S., et al.
Publicado: (2023)

Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER
por: Wang, Xiaowen, et al.
Publicado: (2022)

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

What Type of Patients Did PARAGON-HF Select? Insights from a Real-World Prospective Cohort of Patients with Heart Failure and Preserved Ejection Fraction
por: Rettl, René, et al.
Publicado: (2020)

Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate
por: Butt, Jawad H., et al.
Publicado: (2022)

Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
por: Adamson, Carly, et al.
Publicado: (2022)

Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019
por: Leiva, Orly, et al.
Publicado: (2020)

Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial
por: Butt, Jawad H., et al.
Publicado: (2023)

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF
por: Adamson, Carly, et al.
Publicado: (2022)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER
por: Butt, Jawad H., et al.
Publicado: (2023)

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M., et al.
Publicado: (2022)

Estimating the Lifetime Benefits of Treatments for Heart Failure
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i7bhqesklc946o7vjfgn8pp3h7